Herpetic epithelial keratitis after intravitreal injection of bevacizumab.
Sakarya
Yasar
Y
Sakarya
Rabia
R
Yildirim
Aydin
A
D000212:Acyclovir / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D004279:DNA, Viral / Q000032:analysis; D003930:Diabetic Retinopathy / Q000188:drug therapy; D019573:Epithelium, Corneal / Q000187:drug effects / Q000473:pathology / Q000821:virology*; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007267:Injections; D016849:Keratitis, Herpetic / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D004279:DNA, Viral; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000212:Acyclovir